About: Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective
Creator	Hui, James Murphy, Diarmuid Tan, Sharon Saha, Soura Chiet, Choon Heng, Si
Source	Medline; PMC
abstract	PURPOSE: The review aims to provide a summary of the current literature regarding common medications prescribed in orthopaedic surgery and their potential implications in COVID-19 patients. METHODS: A systematic review was performed using the PRISMA guidelines. All clinical studies, reviews, consensus and guidelines related to the above medications and COVID-19 were included. RESULTS: A total of 18 articles were included. The use of analgesia, anti-inflammatories, steroids, anticoagulants, antibiotics, vitamin B, vitamin C and vitamin D and their potential impact on COVID-19 patients were reported. CONCLUSION: Eight main recommendations were derived from the review. Firstly, paracetamol remains the first line of analgesia and antipyretic. Secondly, there is no need to avoid NSAIDs for COVID-19 patients. Thirdly, opioids have the potential for immunosuppression in addition to respiratory depression and, therefore, should be prescribed with care in COVID-19 patients. Fourthly, patients with conditions where steroids are proven to be efficacious can continue to receive their steroids; otherwise, systemic steroids are not recommended for COVID-19 patients. Fifthly, orthopaedic surgeons following up on COVID-19 patients who are using steroids should continue to follow them up for possible avascular necrosis. Sixthly, whenever possible, oral anticoagulation should be converted to parental heparin. Seventhly, common orthopaedic antibiotics including penicillin and clindamycin are safe to continue for COVID-19 patients. However, for COVID-19 patients, the antibiotics can potentially be switched to macrolides and tetracyclines if the organisms are sensitive. Lastly, prescription for vitamins B, C and D should continue as per usual clinical practice.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1007/s00264-020-04643-5
bibo:pmid	32445030
has license	no-cc
sha1sum (hex)	479a8af031453cd631d370d13ba623f8801de9e8
schema:url	https://doi.org/10.1007/s00264-020-04643-5
resource representing a document's title	Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective
has PubMed Central identifier	PMC7244258
has PubMed identifier	32445030
schema:publication	Int Orthop
resource representing a document's body	covid:479a8af031453cd631d370d13ba623f8801de9e8#body_text
is schema:about of	named entity 'performed' named entity 'aims' named entity 'current literature' named entity 'Medications' named entity 'MEDICATIONS' named entity 'COVID-19' named entity 'COVID-19' named entity 'orthopaedic' named entity 'clinical studies' named entity 'medications prescribed' named entity 'COVID-19' named entity 'current literature' named entity 'NSAIDs' named entity 'Anti-coagulants' named entity 'clinical studies' named entity 'angiotensin-converting' named entity 'analgesia' named entity 'viral replication' named entity 'analgesic' named entity 'oral steroids' named entity 'steroids' named entity 'tetracyclines' named entity 'vitamin' named entity 'anti-inflammatories' named entity 'antibiotics' named entity 'antipyretic' named entity 'steroids' named entity 'stress fractures' named entity 'COVID-19' named entity 'SARS' named entity 'vitamin supplementation' named entity 'clindamycin' named entity 'steroids' named entity 'orthopaedic surgery' named entity 'steroids' named entity 'COVID-19' named entity 'anti-coagulation' named entity 'heparin' named entity 'therapeutic purposes' named entity 'COVID-19' named entity 'unfractionated heparin' named entity 'steroids' named entity 'sepsis' named entity 'steroids' named entity 'metastases' named entity 'Analgesia' named entity 'high-dose' named entity 'neutrophil' named entity 'pain relief' named entity 'elderly patients' named entity 'MERS coronavirus' named entity 'COVID-19' named entity 'vitamin' named entity 'azithromycin' named entity 'anti-coagulant' named entity 'vitamin' named entity 'COVID-19' named entity 'COVID-19' named entity 'steroid' named entity 'NSAIDs' named entity 'infusion' named entity 'hydroxychloroquine' named entity 'middle east respiratory syndrome' named entity 'vitamins' named entity 'cauda equina' named entity 'COVID-19' named entity 'first-line' named entity 'severe acute respiratory syndrome' named entity 'COVID-19 pandemic' named entity 'COVID-19' named entity 'musculoskeletal conditions' named entity 'antiinflammatory medication' named entity 'human plasma' named entity 'inflammatory cytokines' named entity 'MERS' named entity 'steroids'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software